India, May 5 -- Biocryst Pharmaceuticals Inc. (BCRX), while reporting a profit in its first quarter compared to prior year's loss, on Monday said it expects to be profitable for full year 2025, a year ahead of schedule. The company also lifted ORLADEYO revenue guidance.
In pre-market activity on the Nasdaq, Biocryst shares were gaining around 18.7 percent to trade at $10.60.
The company now expects to deliver net income for full year 2025, while previously it was expected for full year 2026.
Global net ORLADEYO revenue is now projected to be between $580 million and $600 million, higher than previously expected $535 million to $550 million.
Operating expenses is now expected to be $440 million to $450 million, higher than previous view ...